Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Current Pharmaceutical Design

Volumn 20, Issue 17, 2014, Pages 2881-2898

  Heinzle, Christine ^a   Erdem, Zeynep ^a   Paur, Jakob ^a   Grasl Kraupp, Bettina ^a   Holzmann, Klaus ^a   Grusch, Michael ^a   Berger, Walter ^a   Marian, Brigitte ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

FGFR4; Targeted therapy

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR;

ALTERNATIVE RNA SPLICING; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CANCER THERAPY; DNA POLYMORPHISM; DRUG SENSITIVITY; EMBRYO DEVELOPMENT; GENE STRUCTURE; GENE TARGETING; GENETIC VARIABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOGENESIS; MUSCLE; NONHUMAN; ONCOGENE; ORGANOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY;

CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84903736685     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990594     Document Type: Review

References (221)

1. Powers CJ, McLeskey SW, and Wellstein A, Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000 7: 165-97.
2. Beenken A and Mohammadi M, The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009 8: 235-53.
3. Heinzle C, Sutterluty H, Grusch M, et al. Targeting fibroblastgrowth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets 2011; 15(7): 829-46.
4. Turner N and Grose R, Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010 10: 116-29.
5. Haugsten EM, Wiedlocha A, Olsnes S, and Wesche J, Roles of Fibroblast Growth Factor Receptors in Carcinogenesis. Mol Cancer Res 2010; 8(11): 1439-52.
6. Knights V and Cook SJ, De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010 125: 105-17.
7. Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, and van der Groep P, Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr-Relat Cancer 2012 19: R115-R129.
8. Hadari Y and Schlessinger J, FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009 119: 1077-9.
9. Holzmann K, Grunt T, Heinzle C, et al. Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer. J Nucleic Acids 2012 2012: 950508.
10. Weinstein M, Xu X, Ohyama K, and Deng CX, FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998 125: 3615-23.
11. Dy G, Emerging systemic therapeutic approaches for personalized medicine in squamous cell carcinoma of the lung. J Cancer Sci Ther 2012 S11: 1-7.
12. Itoh N and Ornitz DM, Evolution of the Fgf and Fgfr gene families. Trends Genet 2004 20: 563-9.
13. Rebscher N, Deichmann C, Sudhop S, et al. Conserved intron positions in FGFR genes reflect the modular structure of FGFR and reveal stepwise addition of domains to an already complex ancestral FGFR. Dev Genes Evol 2009 219: 455-68.
14. Zhang Y, Gorry MC, Post JC, and Ehrlich GD, Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene 1999 230: 69-79.
15. Partanen J, Makela TP, Eerola E, et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 1991 10: 1347-54.
16. Ron D, Reich R, Chedid M, et al. Fibroblast growth factor receptor 4 is a high affinity receptor for both acidic and basic fibroblast growth factor but not for keratinocyte growth factor. J Biol Chem 1993 268: 5388-94.
17. Heinzle C, Gsur A, Hunjadi M, et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res 2012 72: 5767-77.
18. Ornitz DM, Xu J, Colvin JS, et al. Receptor Specificity of the Fibroblast Growth Factor Family. J. Biol. Chem. 1996 271: 15292-15297.
19. Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor Specificity of the Fibroblast Growth Factor Family: the complete mammalian FGF family. J. Biol. Chem. 2006 281: 15694-15700.
20. Hughes SE, Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997 45: 1005-19.
21. Becker M, Brauninger A, Wolf G, Kaufmann M, and Strebhardt K, Identification and functional characterization of the human and murine fibroblast growth factor receptor 4 promoters. Biochem Biophys Res Commun 2000 276: 493-501.
22. Pugh BF and Tjian R, Transcription from a TATA-less promoter requires a multisubunit TFIID complex. Genes Dev 1991 5: 1935-45.
23. Saito H, Kouhara H, Kasayama S, Kishimoto T, and Sato B, Characterization of the promoter region of the murine fibroblast growth factor receptor 1 gene. Biochem Biophys Res Commun 1992 183: 688-93.
24. Avivi A, Skorecki K, Yayon A, and Givol D, Promoter region of the murine fibroblast growth factor receptor 2 (bek/KGFR) gene. Oncogene 1992 7: 1957-62.
25. McEwen DG and Ornitz DM, Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J Biol Chem 1998 273: 5349-57.
26. Perez-Castro AV, Wilson J, and Altherr MR, Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997 41: 10-6.
27. Yu S, Asa SL, and Ezzat S, Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Mol Endocrinol 2002 16: 1069-78.
28. Yu SJ, Zheng L, Ladanyi M, Asa SL, and Ezzat S, Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. Clin Cancer Res 2004 10: 6750-8.
29. Zhao P, Caretti G, Mitchell S, et al. Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem 2006 281: 429-38.
30. Boshnjaku V, Shim KW, Tsurubuchi T, et al. Nuclear localization of folate receptor alpha: a new role as a transcription factor. Sci Rep 2012 2: 980.
31. encode. 2012.
32. Yu S, Asa SL, Weigel RJ, and Ezzat S, Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem 2003 278: 19597-602.
33. Yan G, Wang F, Fukabori Y, et al. Expression and transforming activity of a variant of the heparin-binding fibroblast growth factor receptor (flg) gene resulting from splicing of the alpha exon at an alternate 3'-acceptor site. Biochem Biophys Res Commun 1992 183: 423-30.
34. Vainikka S, Partanen J, Bellosta P, et al. Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 1992 11: 4273-80.
35. Kostrzewa M and Muller U, Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome 1998 9: 131-5.
36. He Y, Smith SK, Day KA, et al. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999 13: 537-45.
37. Tiran Z, Oren A, Hermesh C, et al. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Clin Cancer Res 2008 14: 4612-21.
38. Vorlová S, Rocco G, LeFave Clare V, et al. Induction of Antagonistic Soluble Decoy Receptor Tyrosine Kinases by Intronic PolyA Activation. Mol Cell 2011 43: 927-939.
39. Lemmon MA and Schlessinger J, Cell signaling by receptor tyrosine kinases. Cell 2010 141: 1117-34.
40. Uehara H, Cho Y, Simonis J, et al. Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). FASEB J 2013 27: 76-85.
41. Ezzat S, Zheng L, Yu S, and Asa SL, A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001 287: 60-5.
42. Abbass SAA, Asa SL, and Ezzat S, Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. J Clin Endocrinol Metabol 1997 82: 1160-1166.
43. Takaishi S, Sawada M, Morita Y, et al. Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 2000 267: 658-62.
44. Chen Q, Jiang Y, An Y, et al. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. Biochem Biophys Res Commun 2011 409: 651-656.
45. Keegan K, Johnson DE, Williams LT, and Hayman MJ, Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci USA 1991 88: 1095-9.
46. Rappolee DA, Patel Y, and Jacobson K, Expression of fibroblast growth factor receptors in peri-implantation mouse embryos. Mol Reprod Dev 1998 51: 254-264.
47. Korhonen J, Partanen J, and Alitalo K, Expression of FGFR-4 mRNA in developing mouse tissues. Int J Dev Biol 1992 36: 323-9.
48. Stark KL, McMahon JA, and McMahon AP, FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse. Development 1991 113: 641-51.
49. Powell PP, Wang C-C, Horinouchi H, et al. Differential Expression of Fibroblast Growth Factor Receptors 1 to 4 and Ligand Genes in Late Fetal and Early Postnatal Rat Lung. Am J Respir Cell Mol Biol 1998 19: 563-572.
50. Zhao P and Hoffman EP, Embryonic myogenesis pathways in muscle regeneration. Dev Dyn 2004 229: 380-92.
51. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000 275: 15482-9.
52. Armand A-S, Laziz I, and Chanoine C, FGF6 in myogenesis. Biochim Biophys Acta 2006; 1763: 773-778.
53. Han JK and Martin GR, Embryonic expression of Fgf-6 is restricted to the skeletal muscle lineage. Dev Biol 1993 158: 549-54.
54. Pizette S, Coulier F, Birnbaum D, and DeLapeyriere O, FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells. Exp Cell Res 1996 224: 143-51.
55. Itoh N, Mima T, and Mikawa T, Loss of fibroblast growth factor receptors is necessary for terminal differentiation of embryonic limb muscle. Development 1996 122: 291-300.
56. Armand AS, Launay T, Pariset C, et al. Injection of FGF6 accelerates regeneration of the soleus muscle in adult mice. Biochim Biophys Acta 2003 1642: 97-105.
57. Marics I, Padilla F, Guillemot J-F, Scaal M, and Marcelle C, FGFR4 signaling is a necessary step in limb muscle differentiation. Development 2002 129: 4559-4569.
58. Cool SM, Sayer RE, van Heumen WR, Pickles JO, and Nurcombe V, Temporal and spatial expression of fibroblast growth factor receptor 4 isoforms in murine tissues. Histochem J 2002 34: 291-7.
59. Delfini MC and Duprez D, Ectopic Myf5 or MyoD prevents the neuronal differentiation program in addition to inducing skeletal muscle differentiation, in the chick neural tube. Development 2004 131: 713-23.
60. Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010 70: 6497-508.
61. Lagha M, Kormish JD, Rocancourt D, et al. Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev 2008 22: 1828-37.
62. Lagha M, Sato T, Bajard L, et al. Regulation of skeletal muscle stem cell behavior by Pax3 and Pax7. Cold Spring Harb Symp Quant Biol 2008 73: 307-15.
63. Taylor JGt, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009 119: 3395-407.
64. Tapscott SJ, Thayer MJ, and Weintraub H, Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993 259: 1450-3.
65. Beenken A and Mohammadi M, The structural biology of the FGF19 subfamily. Adv Exp Med Biol 2012 728: 1-24.
66. Kuro-o M, Klotho and betaKlotho. Adv Exp Med Biol 2012 728: 25-40.
67. Lin BC, Wang M, Blackmore C, and Desnoyers LR, Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007 282: 27277-84.
68. Wu X, Ge H, Gupte J, et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 2007 282: 29069-72.
69. Yang C, Jin C, Li X, et al. Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB. PLoS ONE 2012 7: e33870.
70. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 444: 770-4.
71. Luo Y, Yang C, Lu W, et al. Metabolic Regulator %Klotho Interacts with Fibroblast Growth Factor Receptor 4 (FGFR4) to Induce Apoptosis and Inhibit Tumor Cell Proliferation. J Biol Chem 2010 285: 30069-30078.
72. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999 11: 729-35.
73. Miyake A and Itoh N, Rat fibroblast growth factor receptor-4 mRNA in the brain is preferentially expressed in cholinergic neurons in the medial habenular nucleus. Neurosci Lett 1996 203: 101-4.
74. Vincentz JW, McWhirter JR, Murre C, Baldini A, and Furuta Y, Fgf15 is required for proper morphogenesis of the mouse cardiac outflow tract. Genesis 2005 41: 192-201.
75. Gimeno L, Brulet P, and Martinez S, Study of Fgf15 gene expression in developing mouse brain. Gene Expr Patterns 2003 3: 473-81.
76. Nakayama Y, Miyake A, Nakagawa Y, et al. Fgf19 is required for zebrafish lens and retina development. Dev Biol 2008 313: 752-66.
77. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005 2: 217-25.
78. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003 17: 1581-91.
79. Lundasen T, Galman C, Angelin B, and Rudling M, Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006 260: 530-6.
80. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006 12: 1253-5.
81. Portincasa P, Di Ciaula A, Wang HH, et al. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 2008 47: 2112-26.
82. Yu C, Wang F, Jin C, et al. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 2002 161: 2003-10.
83. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011 331: 1621-4.
84. Schaap FG, Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care 2012 15: 386-91.
85. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002 143: 1741-7.
86. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008 57: 1246-53.
87. Nishimura T, Nakatake Y, Konishi M, and Itoh N, Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000 1492: 203-6.
88. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006 55: 2470-8.
89. Izumiya Y, Bina HA, Ouchi N, et al. FGF21 is an Akt-regulated myokine. FEBS Lett 2008 582: 3805-10.
90. Itoh N, Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 2010 342: 1-11.
91. Tomiyama K, Maeda R, Urakawa I, et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010 107: 1666-71.
92. Ding X, Boney-Montoya J, Owen BM, et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012 16: 387-93.
93. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003 112: 683-92.
94. Razzaque MS, The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009 5: 611-9.
95. Consortium. A, Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000 26: 345-8.
96. Kurosu H and Kuro OM, The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009 299: 72-8.
97. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006 281: 6120-3.
98. Gattineni J, Twombley K, Goetz R, Mohammadi M, and Baum M, Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 2011 301: F371-7.
99. Eswarakumar VP, Lax I, and Schlessinger J, Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005 16: 139-49.
100. Loo BM, Kreuger J, Jalkanen M, Lindahl U, and Salmivirta M, Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. J Biol Chem 2001 276: 16868-76.
101. Gao G and Goldfarb M, Heparin can activate a receptor tyrosine kinase. Embo J 1995 14: 2183-90.
102. Kan M, Wu X, Wang F, and McKeehan WL, Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 1999 274: 15947-52.
103. Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000 19: 3309-20.
104. Koziczak M and Hynes NE, Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 2004 279: 50004-11.
105. Shaoul E, Reich-Slotky R, Berman B, and Ron D, Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene 1995 10: 1553-61.
106. Wang JK, Gao G, and Goldfarb M, Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol 1994 14: 181-188.
107. Wang JK and Goldfarb M, Amino acid residues which distinguish the mitogenic potentials of two FGF receptors. Oncogene 1997 14: 1767-78.
108. Cavallaro U, Niedermeyer J, Fuxa M, and Christofori G, N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nat Cell Biol 2001 3: 650-7.
109. Christensen C, Berezin V, and Bock E, Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor. Neuroreport 2011 22: 727-32.
110. Ezzat S, Zheng L, Zhu XF, Wu GE, and Asa SL, Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002 109: 69-78.
111. Ezzat S, Zheng L, and Asa SL, Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004 18: 2543-52.
112. Ezzat S, Zheng L, Winer D, and Asa SL, Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Mol Endocrinol 2006 20: 2965-2975.
113. Pai R, Dunlap D, Qing J, et al. Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating {beta}-Catenin Signaling. Cancer Res 2008 68: 5086-5095.
114. Yokote H, Fujita K, Jing X, et al. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci USA 2005 102: 18866-71.
115. Drafahl KA, McAndrew CW, Meyer AN, Haas M, and Donoghue DJ, The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling. PLoS ONE 2010 5: e14412.
116. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007 446: 153-8.
117. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012 18: 748-57.
118. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008 455: 1069-75.
119. Marks JL, McLellan MD, Zakowski MF, et al. Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4. PLoS ONE 2007 2: e426.
120. Sasaki H, Okuda K, Kawano O, et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 2008 20: 1125-30.
121. Masica DL and Karchin R, Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res 2011 71: 4550-61.
122. Roidl A, Foo P, Wong W, et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010 29: 1543-1552.
123. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008 27: 85-97.
124. French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 2012 7: e36713.
125. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012 12: 56.
126. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002 160: 2295-307.
127. Cheng AL, Shen YC, and Zhu AX, Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology 2011 81: 372-80.
128. Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009 50: 118-27.
129. Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011 19: 347-58.
130. Motoda N, Matsuda Y, Onda M, et al. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Int J Oncol 2011 38: 133-43.
131. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011 50: 397-408.
132. Crose LE, Etheridge KT, Chen C, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012 18: 3780-90.
133. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993 54: 378-82.
134. Penault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995 61: 170-6.
135. Yamada SM, Yamada S, Hayashi Y, et al. Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurol Res 2002 24: 244-8.
136. Zaid T, Yeung TL, Thompson MS, et al. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage High-grade Serous Ovarian Cancer. Clin Cancer Res 2013; 19(4): 809-20.
137. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005 92: 320-7.
138. Murphy T, Darby S, Mathers ME, and Gnanapragasam VJ, Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010 220: 452-60.
139. Yu W, Feng S, Dakhova O, et al. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 2011 17: 4355-66.
140. Sahadevan K, Darby S, Leung HY, et al. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007 213: 82-90.
141. St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005 146: 1145-53.
142. Ezzat S, Huang P, Dackiw A, and Asa SL, Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth. Clin Cancer Res 2005 11: 1336-41.
143. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002 62: 840-7.
144. Wang J, Stockton DW, and Ittmann M, The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004 10: 6169-78.
145. Bargmann CI, Hung MC, and Weinberg RA, Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986 45: 649-57.
146. Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994 371: 252-4.
147. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, and Jabs EW, Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995 11: 462-4.
148. Bellus GA, Spector EB, Speiser PW, et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000 67: 1411-21.
149. Parafioriti A, del Bianco S, Barisani D, et al. Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation. J Orthop Sci 2009 14: 623-30.
150. Webster MK and Donoghue DJ, FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997 13: 178-82.
151. Xu W, Li Y, Wang X, et al. FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects. Eur J Cancer 2010; 46: 3332-8.
152. Frullanti E, Berking C, Harbeck N, et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 2011; 20(4): 340-7.
153. Wang J, Yu W, Cai Y, Ren C, and Ittmann MM, Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008 10: 847-56.
154. Stadler CR, Knyazev P, Bange J, and Ullrich A, FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006 18: 783-94.
155. Seitzer N, Mayr T, Streit S, and Ullrich A, A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 2010 70: 802-12.
156. Francavilla C, Cattaneo P, Berezin V, et al. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J Cell Biol 2009 187: 1101-1116.
157. Sugiyama N, Varjosalo M, Meller P, et al. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci 2010 107: 15786-15791.
158. Nyalendo C, Michaud M, Beaulieu E, et al. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem 2007 282: 15690-9.
159. Ueda J, Kajita M, Suenaga N, Fujii K, and Seiki M, Sequencespecific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003 22: 8716-22.
160. Sugiyama N, Varjosalo M, Meller P, et al. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res 2010 70: 7851-61.
161. Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer 2009 124: 2880-5.
162. Tateno T, Asa SL, Zheng L, et al. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet 2011 7: e1002400.
163. Huang X, Yang C, Jin C, et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009 48: 553-562.
164. Poh W, Wong W, Ong H, et al. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 2012 11: 14.
165. Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012 2: 1118-33.
166. Zhu X, Zheng L, Asa SL, and Ezzat S, Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am J Pathol 2010 177: 2860-9.
167. Brooks AN, Kilgour E, and Smith PD, Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clin Cancer Res 2012 18: 1855-1862.
168. Kumar SB, Narasu L, Gundla R, Dayam R, and J ARPS, Fibroblast growth factor receptor inhibitors. Curr Pharm Des 2013 19: 687-701.
169. Ho HK, Nemeth G, Ng YR, et al. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Curr Med Chem 2013 20: 1203-17.
170. Korc M and Friesel RE, The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009 9: 639-51.
171. Mohammadi M, Froum S, Hamby James M, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998 17: 5896-5904.
172. Koziczak M, Holbro T, and Hynes NE, Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004 23: 3501-8.
173. Loilome W, Joshi A, ap Rhys C, et al. Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neuro-Oncol 2009 94: 359-366.
174. Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 2011 10: 2200-10.
175. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010 53: 4701-19.
176. Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models. Mol Cancer Ther 2012 11: 690-9.
177. Squires M, Ward G, Saxty G, et al. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models. Mol Cancer Ther 2011 10: 1542-1552.
178. Bumbaca D, Wong A, Drake E, et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011 3: 376-86.
179. Roidl A, Berger HJ, Kumar S, et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009 15: 2058-66.
180. Marshall ME, Hinz TK, Kono SA, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 2011 17: 5016-25.
181. Meijer D, Sieuwerts AM, Look MP, et al. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008 15: 101-11.
182. Halatsch ME, Low S, Mursch K, et al. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg 2009 111: 211-8.
183. Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006 24: 3747-55.
184. Serra S, Zheng L, Hassan M, et al. The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. Cancer Res 2012 72: 5683-91.
185. Marme F, Werft W, Benner A, et al. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol 2010 21: 1636-42.
186. Marme F, Hielscher T, Hug S, et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer 2012 131: E586-91.
187. Ansell A, Farnebo L, Grenman R, Roberg K, and Thunell LK, Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009 45: 23-9.
188. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005 65: 7591-5.
189. Jezequel P, Campion L, Joalland MP, et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004 90: 189-93.
190. Spinola M, Leoni VP, Tanuma J, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005 14: 415-9.
191. Naidu R, Har YC, and Taib NA, Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res 2009 18: 65-71.
192. Batschauer AP, Cruz NG, Oliveira VC, et al. HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women. Mol Cell Biochem 2011 357: 247-53.
193. Ma Z, Tsuchiya N, Yuasa T, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008 123: 2574-9.
194. FitzGerald LM, Karlins E, Karyadi DM, et al. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis 2009 12: 192-7.
195. Ho CK, Anwar S, Nanda J, and Habib FK, FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 2010 13: 94-6.
196. Gordon MA, Gil J, Lu B, et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006 7: 67-88.
197. Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004 111: 213-7.
198. da Costa Andrade VC, Parise O, Jr., Hors CP, et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007 82: 53-7.
199. Azad AK, Bairati I, Samson E, et al. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res 2012 18: 196-206.
200. Dutra RL, de Carvalho MB, Dos Santos M, et al. FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx. PLoS ONE 2012 7: e50747.
201. Tanuma J, Izumo T, Hirano M, et al. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep 2010 23: 739-44.
202. Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005 23: 7307-11.
203. Matakidou A, El Galta R, Rudd MF, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007 96: 1904-7.
204. Streit S, Mestel DS, Schmidt M, Ullrich A, and Berking C, FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006 94: 1879-86.
205. Nan H, Qureshi AA, Hunter DJ, and Han J, Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. BMC Cancer 2009 9: 172.
206. Ye Y, Shi Y, Zhou Y, et al. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol 2010 17: 3354-61.
207. Yang Y, Zhou Y, Lu M, et al. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog 2012 51: 515-21.
208. Mawrin C, Kirches E, Diete S, et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006 239: 239-45.
209. Yang YC, Lu ML, Rao JY, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006 95: 1455-8.
210. Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003 98: 2245-50.
211. Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012 72: 2045-56.
212. Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011 54: 7066-83.
213. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008 68: 4774-82.
214. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005 65: 4389-400.
215. Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011 71: 1396-405.
216. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009 101: 1717-23.
217. Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011 10: 1028-35.
218. Dy G, Emerging systemic therapeutic approaches for personalized medicine in squamous cell carcinoma of the lung. J Cancer Sci Ther 2012 S11: 1-7.
219. NCBI. Available from: http://www.ncbi.nlm.nih.gov/gene/ access 2012/ 12/ 15
220. nextProt. Available from: http://www.nextprot.org/ access 2012/ 12/ 15
221. Cavallaro U and Christofori G, Cell adhesion and signalling by cadherins and Ig-CAMS in cancer. Nat Rev Cancer 2004 4: 118-132.